Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Camizestrant plus CDK4/6 inhibitors improved progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to AI and CDK4/6 inhibitors. The SERENA-6 trial used ...

Breast cancer is a leading cause of mortality worldwide. Pharmacological inhibitors of cyclin-dependent kinases (CDK) 4 and 6 (CDK4/6i) inhibit breast cancer growth by inducing a senescent-like state.

The researchers developed the models using a training cohort of 761 patients with HR+/HER2– metastatic breast cancer who received first-line endocrine therapy with CDK4/6 inhibitor combinations ...

Researchers took a deep look at tumor samples from patients with diffuse hemispheric glioma and discovered an unexpected vulnerability to CDK4/6 inhibitors. CDK4/6 inhibitors, which are already ...

Liver biopsy results showed ER+/PR+ IDC with a HER2 IHC score of 0. Comprehensive molecular testing results from ... Her ECOG performance status is 0. Blood-based circulating tumor DNA analysis showed ...

Median PFS almost doubled with the CDK4/6 inhibitor-endocrine combination ... endocrine-refractory HR-positive breast cancer with HER2-low status (IHC 1+ or IHC 2+/in situ hybridization negative).

broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors, in a poster presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8 ...

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired ...